Characterization of entry inhibitors in human cervical & rectal tissue models & d

杀微生物剂在防止HIV-I在粘膜传播中的潜在作用已经很清楚了 已确认身份。然而，对候选杀微生物剂进行严格的临床前评估对于选择 临床试验的最佳化合物，因为这最终将节省成本和时间，考虑到 正式疗效试验的费用和持续时间。对不完全执行疗效试验的关注 最近失败或暂停的第三阶段试验强调了优化后的杀微生物剂候选药物(COL- 1492年，萨维和纤维素硫酸盐)；这些试验表明，开发和配方 有效的杀微生物剂可能不像最初想象的那么容易。而单个核细胞培养和动物 模型可为评估杀微生物剂提供重要信息，解剖、生理和 免疫学问题表明，它们可能不能充分模拟发生在人类粘膜组织中的事件。 因此，针对候选杀微生物剂的临床前开发的综合计划要求 信息是从几个不同的模型系统中积累的。因此，沙托克博士和罗比亚尼博士的团队 已经建立了人类粘膜组织感染HIV-I最早事件的体外模型 树突状细胞驱动的HIV-I传播。这些模型非常适合于测试旨在 阻断HIV-I性传播，并已被广泛用于评估潜在的杀微生物剂候选。 此外，这里描述的实验以及与项目III中描述的实验的交叉验证， 可能确定潜在的有效性、安全性和依从性的生物标志物，这些可能会为未来的临床试验提供信息。 在这个项目中，我们将使用这些已建立的模型来评估HIV-I进入的有效性和兼容性 抑制剂(单独和组合)及其配方。这项研究将受到以下因素的影响和指导 在核心A内开展的工作，将涉及与科学家的广泛互动和合作 主导研究项目II和III。不同小组之间的互动将导致快速跟踪 最有希望在猕猴身上进行评估的抑制剂组合和配方 模型(研究项目III)。

The potential role of microbicides in preventing the mucosal transmission of HIV-i has been clearly identified. However, rigorous pre-clinical evaluation of candidate microbicides is essential to the selection of the best compounds for clinical trials, since this will, in the end, provide savings in costs and time, given the expense and length of formal efficacy trials. Concerns with performing efficacy trials with incompletely optimized microbicide candidates have been highlighted by recent failed or halted Phase III trials (COL- 1492, SAVVY and Cellulose Sulphate); these trials have suggested that development and formulation of effective microbicides may not be as easy as first thought. While mononuclear cell cultures and animal models may provide important information for the evaluation of microbicides, anatomical, physiological and immunological issues suggest they may not adequately model events that occur in human mucosal tissue. Therefore a comprehensive program for pre-clinical development of microbicide candidates requires that information be accrued from several different model systems. Hence Dr. Shattock's and Robbiani's groups have developed in vitro models of the earliest events in HIV-i infection of human mucosal tissue and dendritic cell driven HIV-i spread. These models are ideally suited to test the efficacy of agents designed to block HIV-i sexual transmission and have been widely used to evaluate potential microbicide candidates. Furthermore, experiments described here and cross validation with experiments described in project III, may identify potential biomarkers of efficacy, safety and compliance that could inform future clinical trials. In this project, we will use these established models to evaluate the efficacy and compatibility of HIV-i entry inhibitors (alone and in combination) and their formulations. This research will be influenced and guided by work carried out within Core A, and will involve extensive interactions and collaborations with the scientists leading Research Projects II and III. The interactions between the different groups will result in the fasttracking of the most promising inhibitor combinations and formulations for evaluation in the macaque model (Research Project III).